ROR1-based immunomagnetic protocol allows efficient separation
of CLL and healthy B cells

J 2016

ROR1-based immunomagnetic protocol allows efficient separation of CLL and healthy B cells

KOTAŠKOVÁ, Jana; Šárka PAVLOVÁ; Igor GREIF; Olga STEHLÍKOVÁ; Karla PLEVOVÁ et al.

Základní údaje

Originální název

ROR1-based immunomagnetic protocol allows efficient separation of CLL and healthy B cells

Autoři

KOTAŠKOVÁ, Jana; Šárka PAVLOVÁ ; Igor GREIF; Olga STEHLÍKOVÁ; Karla PLEVOVÁ; Pavlína JANOVSKÁ; Yvona BRYCHTOVÁ; Michael DOUBEK; Šárka POSPÍŠILOVÁ a Vítězslav BRYJA

Vydání

British Journal of Haematology, Hoboken, Wiley-Blackwell, 2016, 0007-1048

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.670

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14310/16:00088845

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova anglicky

ROR1; cell isolation; chronic lymphocytic leukaemia; complete remission

Štítky

AKR, EL OK, podil, rivok

Změněno: 16. 2. 2017 15:48, Mgr. Eva Špillingová

Anotace

V originále

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia among adults in the Western world. This lymphoproliferative disorder is defined by the presence of at least 5 9 106 clonal lymphocytes/ml peripheral blood (Hallek,2015). The biggest clinical challenge is the fact that CLL eradication by any available therapy, apart from allogeneic stem cell transplantation, fails to cure the disease, inducing only temporary disease remission, i.e., when the disease does not manifest clinically but CLL cells still persist in the body. During this phase a population of CLL cells often slowly re-expands to trigger CLL relapse. The relapse is often based on the poorly understood but clinically important process of therapy-driven selection of more aggressive CLL subclones (Malcikova et al, 2015).

Návaznosti

NV15-29793A, projekt VaV

Název: Analýza Wnt/PCP jako nástroj pro lepší management chronické lymfocytární leukémie

Přiložené soubory

1341575.pdf

Požádat o autorskou verzi souboru

Citovat

KOTAŠKOVÁ, Jana; Šárka PAVLOVÁ; Igor GREIF; Olga STEHLÍKOVÁ; Karla PLEVOVÁ; Pavlína JANOVSKÁ; Yvona BRYCHTOVÁ; Michael DOUBEK; Šárka POSPÍŠILOVÁ a Vítězslav BRYJA. ROR1-based immunomagnetic protocol allows efficient separation of CLL and healthy B cells. British Journal of Haematology. Hoboken: Wiley-Blackwell, 2016, roč. 175, č. 2, s. 339-342. ISSN 0007-1048. Dostupné z: https://doi.org/10.1111/bjh.13848.

@article{1341575,
   author = {Kotašková, Jana and Pavlová, Šárka and Greif, Igor and Stehlíková, Olga and Plevová, Karla and Janovská, Pavlína and Brychtová, Yvona and Doubek, Michael and Pospíšilová, Šárka and Bryja, Vítězslav},
   article_location = {Hoboken},
   article_number = {2},
   doi = {https://doi.org/10.1111/bjh.13848},
   keywords = {ROR1; cell isolation; chronic lymphocytic leukaemia; complete remission},
   language = {eng},
   issn = {0007-1048},
   journal = {British Journal of Haematology},
   title = {ROR1-based immunomagnetic protocol allows efficient separation of CLL and healthy B cells},
   url = {http://onlinelibrary.wiley.com/doi/10.1111/bjh.13848/epdf},
   volume = {175},
   year = {2016}
}

TY  - JOUR
ID  - 1341575
AU  - Kotašková, Jana - Pavlová, Šárka - Greif, Igor - Stehlíková, Olga - Plevová, Karla - Janovská, Pavlína - Brychtová, Yvona - Doubek, Michael - Pospíšilová, Šárka - Bryja, Vítězslav
PY  - 2016
TI  - ROR1-based immunomagnetic protocol allows efficient separation of CLL and healthy B cells
JF  - British Journal of Haematology
VL  - 175
IS  - 2
SP  - 339-342
EP  - 339-342
PB  - Wiley-Blackwell
SN  - 00071048
KW  - ROR1
KW  - cell isolation
KW  - chronic lymphocytic leukaemia
KW  - complete remission
UR  - http://onlinelibrary.wiley.com/doi/10.1111/bjh.13848/epdf
L2  - http://onlinelibrary.wiley.com/doi/10.1111/bjh.13848/epdf
N2  - Chronic lymphocytic leukaemia (CLL) is the most common leukaemia among adults in the Western world. This lymphoproliferative disorder is defined by the presence of at least 5 9 106 clonal lymphocytes/ml peripheral blood (Hallek,2015). The biggest clinical challenge is the fact that CLL eradication by any available therapy, apart from allogeneic stem cell transplantation, fails to cure the disease, inducing only temporary disease remission, i.e., when the disease does not manifest clinically but CLL cells still persist in the body. During this phase a population of CLL cells often slowly re-expands to trigger CLL relapse. The relapse is often based on the poorly understood but clinically important process of therapy-driven selection of more aggressive CLL subclones (Malcikova et al, 2015).
ER  -

KOTAŠKOVÁ, Jana; Šárka PAVLOVÁ; Igor GREIF; Olga STEHLÍKOVÁ; Karla PLEVOVÁ; Pavlína JANOVSKÁ; Yvona BRYCHTOVÁ; Michael DOUBEK; Šárka POSPÍŠILOVÁ a Vítězslav BRYJA. ROR1-based immunomagnetic protocol allows efficient separation of CLL and healthy B cells. \textit{British Journal of Haematology}. Hoboken: Wiley-Blackwell, 2016, roč.~175, č.~2, s.~339-342. ISSN~0007-1048. Dostupné z: https://doi.org/10.1111/bjh.13848.

Přehled o publikaci